The Proven Framework for Turning Biotech Leadership Summits into Lasting Partnerships

A summit can open a door. A partnership takes shape through what happens before the meeting, in the room and in the weeks that follow.

For biotech leaders, the opportunity is not simply to meet more people. It is to identify where scientific or strategic priorities align, establish trust, and agree on a next step that both organisations can support. That takes preparation and follow-through, not just a busy calendar.

The framework below offers five practical stages: define, prepare, convene, progress and govern. It applies to potential industry collaborations, research relationships and broader partnerships across the vaccine ecosystem.

1. Define the partnership purpose

Start with a clear view of what your organisation hopes to explore. “Find partners” is too broad to guide good decisions. Identify the capabilities, expertise or access that could help advance a specific programme or priority.

Consider:

• Strategic fit: Which health need, geography or organisational priority is relevant?
• Scientific fit: What evidence, technology or expertise could complement your work?
• Partnership form: Are you exploring research, development, licensing, investment or another arrangement?
• Decision path: Which scientific, business-development and executive stakeholders may need to be involved?

This focus helps a team distinguish a promising connection from a conversation that is interesting but not actionable. It also helps ensure different representatives tell a consistent story.

Summits bring together leaders from across science, policy and industry. The Global Vaccine Leadership Summit’s London and Boston editions are designed around this broader dialogue. The goal is not to presume a deal, but to create space for relevant conversations to begin.

2. Prepare a credible, concise case

A partner needs to understand what you are working on, why it matters and what kind of conversation you are seeking. Prepare a short, non-confidential overview that covers the unmet need, your approach, available evidence, key risks and the next question you want to explore.

Separate this overview from the materials intended for confidential diligence. Be clear about what can be shared openly, what requires an appropriate agreement and who in your organisation can provide further information.

Preparation should include the limits of the opportunity as well as its potential. Recent guidance from A&O Shearman on pharma partnering highlights that pharma teams consider scientific merit, strategic fit and development potential together. It also notes the value of tailored materials and candid discussion of scientific, clinical and regulatory risks.

For each priority meeting, prepare two or three questions. For example: What evidence would help your team assess this opportunity? Which stakeholders would need to be part of a follow-up discussion? What kind of collaboration would be relevant to your current priorities?

3. Make the meeting useful to both sides

The first conversation is a chance to test mutual fit, not to force a conclusion. Begin with the other organisation’s priorities. Then explain the part of your work that relates directly to those priorities.

A simple meeting structure can keep the discussion focused:

1. Listen: Understand the other party’s objectives and constraints.
2. Explore: Compare scientific, operational and strategic priorities.
3. Agree: Identify one useful next step, or acknowledge that the timing or fit is not right.

This approach respects limited time and makes it easier to recognise both alignment and gaps. It also leaves room for questions that may not be resolved in one conversation.

Research on structured scientific conferences offers a useful, but qualified, insight. In a study of four Scialog conferences, participants who later collaborated had 63% more interaction on average than those who did not. The researchers also found a strong association between participation in small-group sessions and collaboration formation. These were deliberately structured science meetings, not a test of commercial biotech partnerships, so the findings should not be treated as a prediction of deal outcomes. They do, however, support a practical principle: substantive interaction matters. Read the study.

For summit hosts and participants alike, this points to the value of purposeful formats: focused roundtables, facilitated introductions and time for considered one-to-one discussion. The Global Vaccine Leadership Summit experience is built around leadership dialogue, scientific discussion and purposeful connection.

4. Turn interest into a documented next step

A positive conversation is a beginning, not evidence that a partnership is underway. Before the meeting ends, clarify what each party is willing to do next. That might be a technical discussion, an introduction to a colleague, a review of non-confidential material or a decision to reconnect at a later stage.

Afterward, record the essentials while they are still fresh:

• The shared priority or potential fit.
• Open questions, concerns or evidence gaps.
• The people who should be included next.
• The action, owner and proposed timing.

A brief, personal follow-up can then confirm the discussion, answer any agreed question and suggest the next step. Send only materials that are appropriate to share, and avoid implying commitment where none has been made.

It is useful to review progress at defined intervals, such as one week, two weeks and one month after the summit. Track movement rather than volume: follow-up conversations, introductions to relevant decision-makers, requests for further information, or a jointly agreed workplan. If there is no current fit, record that clearly and respectfully.

This discipline matters because momentum can fade after an encouraging first meeting. The A&O Shearman article notes that biotech teams can support an internal champion by responding promptly and providing materials that help the champion explain the opportunity within their organisation.

5. Build the operating model early

When a conversation advances, shift from interest to execution. Discuss what each organisation wants the collaboration to achieve, what each will contribute, and how progress or difficult decisions will be managed.

Topics to clarify include:

• Objectives, scope and milestones.
• Roles, decision rights and points of contact.
• Data, intellectual property and confidentiality.
• Resourcing, review cadence and escalation routes.
• Measures of progress and conditions for reassessing the work.

The precise structure will depend on the partnership. A research collaboration, a licence and a development alliance have different requirements. Legal, scientific, commercial and alliance-management expertise may all be needed as discussions become more specific.

The 2024 State of Pharma Alliance Management report describes execution and coordination as continuing challenges for life-sciences alliances. Its findings reflect the report’s surveyed organisations, rather than a universal forecast. The practical lesson is still relevant: establish ownership and communication early, rather than treating partnership management as an administrative handover after an agreement is signed.

A simple summit-to-partnership checklist

Before: Define the partnership purpose, identify relevant organisations and stakeholders, and prepare a concise, evidence-led introduction.

During: Listen for priorities, discuss fit candidly and agree on an appropriate next step.

After: Record actions, follow up with relevant information, involve the right colleagues and review progress at set intervals.

A lasting partnership is not guaranteed by attendance or a single strong conversation. It becomes more possible when the right people meet around a shared purpose, test their assumptions and carry agreed actions forward.

The Global Vaccine Leadership Summit brings together senior leaders from vaccine innovation, global health policy, science and industry for focused dialogue. To learn more about the 2027 editions, explore the London and Boston pages or request the summit brochure.